Cardiovascular disease (CVD) is the #1 cause of death worldwide despite available treatments.
Hundreds of millions of people are living with atherosclerotic cardiovascular disease (ASCVD), a subset of CVD, worldwide.
One person dies every 34 seconds from CVD in the U.S.
There are approximately 800,000 heart attacks each year in the U.S.
Verve is meeting this challenge head-on through the development of groundbreaking, single-course gene editing medicines.
Verve was purpose-built to disrupt today’s chronic care model for CVD, with a team of experts in cardiovascular medicine, genetics, gene editing, delivery technologies and drug development.Meet our team
heart-1 is currently enrolling patients with heterozygous familial hypercholesterolemia (HeFH) in the United Kingdom and New Zealand.
HeFH is a form of familial hypercholesterolemia that is genetically driven, and causes lifelong, severely elevated LDL-C levels.
Our vision, values, talent and strategy have been purpose-built to protect the world from cardiovascular disease. To do so requires the deep passion and drive that are inherent to our team at Verve.